Why Mild Transaminitis Matters in Patients on Biologics and Steroids
Even mild transaminitis in patients on biologics and steroids demands immediate attention because these medications can cause drug-induced autoimmune-like hepatitis (DI-AILH) that may progress to acute liver failure requiring transplantation in up to 14% of cases, despite the absence of symptoms 1.
The Critical Risk: Drug-Induced Liver Injury Can Be Silent but Deadly
Biologics (especially anti-TNF agents) are well-established hepatotoxins
The 2025 British Society of Gastroenterology guidelines specifically identify anti-TNF biologics as causative agents for DI-AILH 1. This condition:
- Can progress rapidly despite mild initial presentation
- Presents with elevated transaminases in 40-80% of cases with positive autoantibodies
- May show interface hepatitis on biopsy even when transaminases are only mildly elevated
- Progresses to acute liver failure in some patients, with 14% requiring liver transplantation 1
The absence of symptoms is misleading and dangerous
Asymptomatic patients with elevated transaminases have similar severity of necro-inflammation and fibrosis as symptomatic patients, with equivalent death/transplantation rates 1. The lack of abdominal symptoms or disease flare provides false reassurance—the liver injury is occurring regardless of symptoms.
What You're Actually Detecting: Three Dangerous Scenarios
1. Drug-Induced Autoimmune-Like Hepatitis (DI-AILH)
- Latency often exceeds 3 months on the drug before presentation 1
- Serum IgG elevated in 25-40% of cases
- Interface hepatitis present on biopsy
- Can present as acute liver failure 1
2. Unmasking of Underlying Autoimmune Hepatitis
- Biologics and steroids may have been suppressing an underlying autoimmune process
- 24% of patients with unexplained chronic hepatitis have interface hepatitis with measurable autoantibodies 2
- Cirrhosis found in 5 of 150 patients with "mild" transaminitis in one series 2
3. Progressive Fibrosis Without Symptoms
- One-third of AIH patients have cirrhosis at diagnosis 1
- Elevated transaminases (even mild) are associated with increased all-cause mortality 3
- Fibrosis progression occurs silently
The Algorithmic Approach: What to Do Now
Immediate Actions (Week 1):
- Obtain comprehensive drug history including all biologics, steroids, and any other medications 1
- Repeat transaminases within 1 week to assess trajectory 1
- Check baseline labs: CBC with platelets, glucose, lipid profile, HBsAg, HCV antibody, albumin, iron studies, ferritin, IgG levels, ANA, anti-smooth muscle antibody 3
- Calculate FIB-4 Index to assess fibrosis risk 3
Decision Points Based on Initial Assessment:
If transaminases fail to fall substantially within 1 week OR any of the following present:
- Jaundice develops
- INR > 1.5
- Albumin declining
- → Proceed immediately to liver biopsy 1
If transaminases are rising or persistently elevated (>2 weeks):
- Consider stopping the biologic (strong recommendation from BSG guidelines) 1
- Liver biopsy if no prompt resolution after drug withdrawal 1
If biopsy shows:
- Advanced fibrosis → Start prednisolone 0.5 mg/kg/day (up to 40 mg/day) 1
- Interface hepatitis → Treat as autoimmune hepatitis 1
- Any evidence of cirrhosis → Refer to hepatology immediately 1
Critical Pitfalls to Avoid
Pitfall #1: Waiting for symptoms
The data is unequivocal—symptoms do not correlate with disease severity. Asymptomatic patients die at the same rate as symptomatic ones 1.
Pitfall #2: Assuming steroids are protective
While patients are already on steroids, these may be masking symptoms while liver injury progresses. DI-AILH can occur despite concurrent steroid use 1.
Pitfall #3: Attributing transaminitis to the underlying disease
Without abdominal symptoms or disease flare, the transaminitis is more likely drug-related than disease-related. The BSG guidelines give a strong recommendation to routinely consider DI-AILH and promptly stop the suspected drug 1.
Pitfall #4: Re-challenging with the same biologic
Re-exposure to the initially implicated drug is hazardous and rarely justified when alternatives exist 1. Even switching to a different drug in the same class has been done successfully in some cases 1.
The Bottom Line on Monitoring
Patients on biologics require:
- Transaminase monitoring every 3-4 weeks initially, then every 3 months during stable therapy 4
- Immediate investigation of any elevation, even if mild
- Low threshold for liver biopsy if elevation persists beyond 1-2 weeks after drug withdrawal 1
The immunosuppression these patients are receiving creates a perfect storm: it may mask symptoms while allowing progressive liver injury, and the drugs themselves are hepatotoxic. Mild transaminitis is your only warning sign before potential acute liver failure.